Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

127
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
127
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

78
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
78

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Patient Perception of Degree of Subglottic Stenosis and Exam Findings.

Ear, nose, & throat journal·2026
Same author

ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?

Annals of surgical oncology·2026
Same author

Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization.

Critical care explorations·2026
Same author

Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?

Annals of surgical oncology·2026
Same author

The Association of Extended Venous Thromboembolism Prophylaxis and Venous Thromboembolism After Cancer Surgery.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Financial Toxicity Following Locally Advanced Rectal Cancer Treatment.

Diseases of the colon and rectum·2026

Related Experiment Video

Updated: Jun 15, 2025

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

3.8K

Complete pathologic response in esophageal adenocarcinoma: does it make a difference?

Britton B Donato1,2, Megan E Campany3, Justin T Brady4

  • 1Department of Surgery, Mayo Clinic, Phoenix, AZ, USA.

Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|August 22, 2024
PubMed
Summary

Achieving complete pathologic response after neoadjuvant therapy for esophageal adenocarcinoma significantly improves survival. This finding highlights the importance of identifying patients who achieve complete response for better prognostication and treatment planning.

Keywords:
complete pathologic responseesophageal adenocarcinomasurvival trend

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

391
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.5K

Related Experiment Videos

Last Updated: Jun 15, 2025

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

3.8K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

391
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.5K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Neoadjuvant therapy advancements for esophageal adenocarcinoma offer potential for complete pathologic response (pCR).
  • Limited data exist on the incidence and survival implications of pCR in esophageal adenocarcinoma patients.
  • Understanding pCR is crucial for refining treatment strategies and patient counseling.

Purpose of the Study:

  • To evaluate the trend of complete pathologic response (pCR) in esophageal adenocarcinoma patients.
  • To identify predictors of pCR in this patient population.
  • To assess the survival impact of pCR following trimodal therapy and esophagectomy.

Main Methods:

  • Analysis of the National Cancer Database (NCDB) for 16,169 patients with esophageal adenocarcinoma.
  • Inclusion criteria: trimodal therapy including esophagectomy (2006-2020).
  • Evaluation of patient factors, staging, and survival outcomes related to pCR.

Main Results:

  • 11.4% of patients achieved pCR; this rate increased to 17.5% in 2016-2020.
  • Predictors of pCR included female sex, Black race, Hispanic ethnicity, and later diagnosis era.
  • Clinical stage II disease increased pCR probability, while stage III decreased it.
  • pCR was associated with significantly improved median survival (86.4 months vs. 30.7 months) and 4-year survival (63.3% vs. 39.2%).

Conclusions:

  • Complete pathologic response in esophageal adenocarcinoma confers a substantial survival advantage.
  • These findings support improved identification of complete clinical response before esophagectomy.
  • Knowledge of pCR impacts patient counseling, prognostication, and surveillance strategies.